{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T05:11:18Z","timestamp":1790226678004,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"DOI":"10.1186\/s12894-025-01734-6","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T09:24:05Z","timestamp":1741771445000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Factors predicting local or systemic side effects related to intravesical BCG (Bacillus Calmette-Gu\u00e9rin) therapy: a retrospective observational study"],"prefix":"10.1186","volume":"25","author":[{"given":"Tugay","family":"Aksakalli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adem","family":"Utlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feyzullah","family":"Celik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet Emre","family":"Cinislioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saban Oguz","family":"Demirdogen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhittin","family":"Atar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Karabulut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,12]]},"reference":[{"key":"1734_CR1","unstructured":"EAU Guidelines. Edn. presented at the EAU Annual Congress Milan 2023. ISBN 978-94-92671-19-6."},{"issue":"4","key":"1734_CR2","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/j.1464-410X.2003.04655.x","volume":"93","author":"MD Shelley","year":"2004","unstructured":"Shelley MD, Wilt TJ, Court J, Coles B, Kynaston H, Mason MD. Intravesical bacillus Calmette-Gu\u00e9rin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int. 2004;93(4):485\u201390.","journal-title":"BJU Int"},{"issue":"5","key":"1734_CR3","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","volume":"57","author":"RJ Sylvester","year":"2010","unstructured":"Sylvester RJ, Brausi MA, Kirkels WJ, Hoeltl W, Calais Da Silva F, Powell PH, et al. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Gu\u00e9rin, and bacillus Calmette-Gu\u00e9rin plus Isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol. 2010;57(5):766\u201373.","journal-title":"Eur Urol"},{"issue":"1","key":"1734_CR4","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","volume":"169","author":"A B\u00f6hle","year":"2003","unstructured":"B\u00f6hle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol. 2003;169(1):90\u20135.","journal-title":"J Urol"},{"key":"1734_CR5","doi-asserted-by":"crossref","unstructured":"Rousseau M, O\u2019brien CJ, Antequera E, Zdimerova H, Cansever D, Canton T et al. Identification of sex differences in tumor-specific T cell infiltration in bladder tumor-bearing mice treated with BCG immunotherapy. 2020;6(4):507\u201324.","DOI":"10.3233\/BLC-200384"},{"issue":"5","key":"1734_CR6","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.eururo.2020.04.066","volume":"78","author":"MO Grimm","year":"2020","unstructured":"Grimm MO, van der Heijden AG, Colombel M, Muilwijk T, Mart\u00ednez-Pi\u00f1eiro L, Babjuk MM, et al. Treatment of High-grade Non-muscle-invasive bladder carcinoma by standard number and dose of BCG instillations versus reduced number and standard dose of BCG instillations: results of the European association of urology research foundation randomised phase III clinical trial NIMBUS. Eur Urol. 2020;78(5):690\u20138.","journal-title":"Eur Urol"},{"issue":"4","key":"1734_CR7","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S0302-2838(03)00357-9","volume":"44","author":"AP van der Meijden","year":"2003","unstructured":"van der Meijden AP, Sylvester RJ, Oosterlinck W, Hoeltl W, Bono AV. Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European organisation for research and treatment of Cancer Genito-Urinary group phase III trial. Eur Urol. 2003;44(4):429\u201334.","journal-title":"Eur Urol"},{"issue":"6","key":"1734_CR8","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1111\/bju.14793","volume":"124","author":"ES Larsen","year":"2019","unstructured":"Larsen ES, Nordholm AC, Lillebaek T, Holden IK, Johansen IS. The epidemiology of Bacille Calmette-Gu\u00e9rin infections after bladder instillation from 2002 through 2017: a nationwide retrospective cohort study. BJU Int. 2019;124(6):910\u20136.","journal-title":"BJU Int"},{"issue":"1","key":"1734_CR9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.eururo.2013.07.021","volume":"65","author":"M Brausi","year":"2014","unstructured":"Brausi M, Oddens J, Sylvester R, Bono A, van de Beek C, van Andel G, et al. Side effects of Bacillus Calmette-Gu\u00e9rin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol. 2014;65(1):69\u201376.","journal-title":"Eur Urol"},{"issue":"3","key":"1734_CR10","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/bju.13474","volume":"118","author":"JR Oddens","year":"2016","unstructured":"Oddens JR, Sylvester RJ, Brausi MA, Kirkels WJ, van de Beek C, van Andel G, et al. Increasing age is not associated with toxicity leading to discontinuation of treatment in patients with urothelial non-muscle-invasive bladder cancer randomised to receive 3 years of maintenance Bacille Calmette-Gu\u00e9rin: results from European organisation for research and treatment of Cancer Genito-Urinary group study 30911. BJU Int. 2016;118(3):423\u20138.","journal-title":"BJU Int"},{"issue":"4","key":"1734_CR11","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","volume":"79","author":"RJ Sylvester","year":"2021","unstructured":"Sylvester RJ, Rodr\u00edguez O, Hern\u00e1ndez V, Turturica D, Bauerov\u00e1 L, Bruins HM, et al. European association of urology (EAU) prognostic factor risk groups for Non-muscle-invasive bladder Cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC guidelines panel. Eur Urol. 2021;79(4):480\u20138.","journal-title":"Eur Urol"},{"issue":"1","key":"1734_CR12","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.euo.2021.11.006","volume":"5","author":"N Lobo","year":"2022","unstructured":"Lobo N, Hensley PJ, Bree KK, Nogueras-Gonzalez GM, Navai N, Dinney CP, et al. Updated European association of urology (EAU) prognostic factor risk groups overestimate the risk of progression in patients with Non-muscle-invasive bladder Cancer treated with Bacillus Calmette-Gu\u00e9rin. Eur Urol Oncol. 2022;5(1):84\u201391.","journal-title":"Eur Urol Oncol"},{"issue":"4","key":"1734_CR13","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","volume":"163","author":"DL Lamm","year":"2000","unstructured":"Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Maintenance bacillus calmette-guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized southwest oncology group study, et al. J Urol. 2000;163(4):1124\u20139.","journal-title":"J Urol"},{"issue":"10","key":"1734_CR14","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.eursup.2008.08.001","volume":"7","author":"JA Witjes","year":"2008","unstructured":"Witjes JA, Palou J, Soloway M, Lamm D, Brausi M, Spermon JR, et al. Clinical practice recommendations for the prevention and management of intravesical Therapy\u2013Associated adverse events. Eur Urol Supplements. 2008;7(10):667\u201374.","journal-title":"Eur Urol Supplements"},{"key":"1734_CR15","doi-asserted-by":"crossref","unstructured":"Serretta V. BCG and bladder cancer. Forty-eight years after Morales report. Urologia. 2024:3915603241252909.","DOI":"10.1177\/03915603241252909"},{"issue":"7","key":"1734_CR16","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1046\/j.1464-410X.2002.02722.x","volume":"89","author":"JA Mart\u00ednez-Pi\u00f1eiro","year":"2002","unstructured":"Mart\u00ednez-Pi\u00f1eiro JA, Flores N, Isorna S, Solsona E, Sebasti\u00e1n JL, Pertusa C, et al. Long-term follow-up of a randomized prospective trial comparing a standard 81\u00a0mg dose of intravesical Bacille Calmette-Gu\u00e9rin with a reduced dose of 27\u00a0mg in superficial bladder cancer. BJU Int. 2002;89(7):671\u201380.","journal-title":"BJU Int"},{"issue":"5","key":"1734_CR17","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1016\/S0022-5347(05)00970-5","volume":"175","author":"BA Inman","year":"2006","unstructured":"Inman BA, Re. Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol. 2006;175(5):1960. author reply\u2013\u20091.","journal-title":"J Urol"},{"issue":"5","key":"1734_CR18","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1016\/j.eururo.2007.04.062","volume":"52","author":"A Ojea","year":"2007","unstructured":"Ojea A, Nogueira JL, Solsona E, Flores N, G\u00f3mez JM, Molina JR, et al. A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27\u00a0mg) versus very low-dose bacillus Calmette-Guerin (13.5\u00a0mg) versus mitomycin C. Eur Urol. 2007;52(5):1398\u2013406.","journal-title":"Eur Urol"},{"issue":"3","key":"1734_CR19","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","volume":"63","author":"J Oddens","year":"2013","unstructured":"Oddens J, Brausi M, Sylvester R, Bono A, van de Beek C, van Andel G, et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol. 2013;63(3):462\u201372.","journal-title":"Eur Urol"},{"issue":"5","key":"1734_CR20","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/j.1464-410X.2009.08469.x","volume":"104","author":"R Damiano","year":"2009","unstructured":"Damiano R, De Sio M, Quarto G, Di Lorenzo G, Perdon\u00e0 S, Palumbo IM, et al. Short-term administration of Prulifloxacin in patients with nonmuscle-invasive bladder cancer: an effective option for the prevention of bacillus Calmette-Gu\u00e9rin-induced toxicity? BJU Int. 2009;104(5):633\u20139.","journal-title":"BJU Int"},{"issue":"4","key":"1734_CR21","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S0302-2838(03)00357-9","volume":"44","author":"APM van der Meijden","year":"2003","unstructured":"van der Meijden APM, Sylvester RJ, Oosterlinck W, Hoeltl W, Bono AV. Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European organisation for research and treatment of Cancer Genito-Urinary group phase III trial. Eur Urol. 2003;44(4):429\u201334.","journal-title":"Eur Urol"},{"issue":"4","key":"1734_CR22","doi-asserted-by":"publisher","first-page":"361","DOI":"10.4111\/icu.20240080","volume":"65","author":"H Lee","year":"2024","unstructured":"Lee H, So S, Cho MC, Cho SY, Paick JS, Oh SJ. Clinical outcomes of holmium laser enucleation of the prostate: A large prospective registry-based patient cohort study under regular follow-up protocol. Invest Clin Urol. 2024;65(4):361\u20137.","journal-title":"Invest Clin Urol"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-025-01734-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-025-01734-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-025-01734-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T20:49:40Z","timestamp":1741812580000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-025-01734-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,12]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1734"],"URL":"https:\/\/doi.org\/10.1186\/s12894-025-01734-6","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,12]]},"assertion":[{"value":"10 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the University of Health Sciences, Erzurum Medicine Faculty Scientific Research Ethics Committee. This study was conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was taken from all participants to participate in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"BAEK 2024\/04\u201390.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"All authors declare no potential conflict of interest with this publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The authors declare no competing interests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"49"}}